More stringent conditions of plasmid DNA vaccination are required to protect grafted versus endogenous islets in nonobese diabetic mice

J Immunol. 2003 Jul 1;171(1):469-76. doi: 10.4049/jimmunol.171.1.469.

Abstract

Recurrent autoimmune destruction of the insulin-producing beta cells is a key factor limiting successful islet graft transplantation in type I diabetic patients. In this study, we investigated the feasibility of using an Ag-specific plasmid DNA (pDNA)-based strategy to protect pro-islets that had developed from a neonatal pancreas implanted under the kidney capsule of nonobese diabetic (NOD) mice. NOD recipient mice immunized with pDNA encoding a glutamic acid decarboxylase 65 (GAD65)-IgFc fusion protein (JwGAD65), IL-4 (JwIL4), and IL-10 (pIL10) exhibited an increased number of intact pro-islets expressing high levels of insulin 15 wk posttransplant, relative to NOD recipient mice immunized with pDNA encoding a hen egg lysozyme (HEL)-IgFc fusion protein (JwHEL)+JwIL4 and pIL10 or left untreated. Notably, the majority of grafted pro-islets detected in JwGAD65+JwIL4- plus pIL10-treated recipients was free of insulitis. In addition, administration of JwGAD65+JwIL4+pIL10 provided optimal protection for engrafted islets compared with recipient NOD mice treated with JwGAD65+JwIL4 or JwGAD65+pIL10, despite effective protection of endogenous islets mediated by the respective pDNA treatments. Efficient protection of pro-islet grafts correlated with a marked reduction in GAD65-specific IFN-gamma reactivity and an increase in IL-10-secreting T cells. These results demonstrate that pDNA vaccination can be an effective strategy to mediate long-term protection of pro-islet grafts in an Ag-specific manner and that conditions are more stringent to suppress autoimmune destruction of grafted vs endogenous islets.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 1 / genetics
  • Diabetes Mellitus, Type 1 / immunology*
  • Diabetes Mellitus, Type 1 / pathology
  • Diabetes Mellitus, Type 1 / prevention & control*
  • Female
  • Glutamate Decarboxylase / administration & dosage
  • Glutamate Decarboxylase / genetics
  • Glutamate Decarboxylase / therapeutic use
  • Immunoglobulin Fc Fragments / administration & dosage
  • Immunoglobulin Fc Fragments / genetics
  • Immunoglobulin Fc Fragments / therapeutic use
  • Injections, Intramuscular
  • Interferon-gamma / antagonists & inhibitors
  • Interferon-gamma / metabolism
  • Interleukin-10 / administration & dosage
  • Interleukin-10 / genetics
  • Interleukin-10 / therapeutic use
  • Interleukin-4 / administration & dosage
  • Interleukin-4 / genetics
  • Interleukin-4 / metabolism
  • Interleukin-4 / therapeutic use
  • Islets of Langerhans / immunology*
  • Islets of Langerhans / pathology*
  • Islets of Langerhans Transplantation / immunology*
  • Islets of Langerhans Transplantation / methods*
  • Islets of Langerhans Transplantation / pathology
  • Isoenzymes / administration & dosage
  • Isoenzymes / genetics
  • Isoenzymes / therapeutic use
  • Mice
  • Mice, Inbred NOD
  • Plasmids / administration & dosage
  • Plasmids / immunology*
  • Plasmids / therapeutic use
  • Transplantation, Isogeneic
  • Up-Regulation / genetics
  • Up-Regulation / immunology
  • Vaccines, DNA / administration & dosage
  • Vaccines, DNA / immunology*
  • Vaccines, DNA / therapeutic use

Substances

  • Immunoglobulin Fc Fragments
  • Isoenzymes
  • Vaccines, DNA
  • Interleukin-10
  • Interleukin-4
  • Interferon-gamma
  • Glutamate Decarboxylase
  • glutamate decarboxylase 2